Bausch & Lomb Incorporated

Is this e-mail not displaying correctly? View this e-mail in your browser.


	Indication \| Important Safety Information \| Full Prescribing Information


	Allergy season has arrived Click here to learn more about relieving the signs and symptoms of seasonal allergic conjunctivitis (SAC).


	Treat the signs and symptoms of SAC with a low risk of significant IOP* elevations ALREX^® (loteprednol etabonate ophthalmic suspension 0.2%) effectively relieves the signs and symptoms associated with SAC, including itching, burning/stinging, discomfort, foreign body sensation, tearing, redness, and swelling^1-3 ALREX has an established safety profile with a low risk of significant IOP elevations^2,3
	In two 6-week safety and efficacy trials in patients with SAC: ALREX demonstrated IOP elevations similar to placebo^1-3,†

To learn more about ALREX, visit our Web site at www.bausch.com.

*Intraocular pressure.
^†In randomized, double-masked, placebo-controlled, parallel-group, multicenter studies in which patients with SAC received either ALREX or placebo 4 times daily for 42 days. In summation of the 2 studies, 1 out of 133 patients experienced IOP elevations ≥10 mm Hg in the ALREX group; 1 out of 135 patients experienced IOP elevations ≥10 mm Hg in the placebo group.^1-3

Indication

ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis

Important Safety Information

As with other ophthalmic corticosteroids, ALREX is contraindicated in most viral diseases of the cornea and conjunctiva, and in mycobacterial and fungal diseases of the eye. Prolonged use of corticosteroids may result in secondary glaucoma, cataract formation, and secondary ocular infections following suppression of the host immune response and/or perforation of the globe. The renewal of the medication order beyond 14 days should be made by a physician only after examination with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If this product is used for 10 days or longer, intraocular pressure should be monitored
The most common adverse events in patients treated with ALREX were abnormal vision, blurring, burning, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, and photophobia. Non-ocular adverse reactions include headache, rhinitis, and pharyngitis

Please view the full prescribing information for ALREX.

References:
1.	Alrex^® Prescribing Information, August 2008.
2.	Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102(2):251-255.
3.	Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106(2):362-369.

ALREX is a registered trademark of Bausch & Lomb Incorporated.
© 2010 Bausch & Lomb Incorporated. PH3021 3/10

Bausch & Lomb (Global Pharmaceutical Headquarters)
7 Giralda Farms, Suite 1001
Madison, NJ 07940
Customer Service: 1-800-323-0000

If you no longer wish to receive e-mails from Bausch + Lomb about loteprednol etabonate products, unsubscribe here.